Fennec Pharmaceuticals Inc.

NASDAQ:FENC

Biotechnology

Healthcare
$13.33 -1.34%

-$0.12 today

Market cap
$470.62M
Beta
1.08
P/E (TTM)
-36.3
EPS (TTM)
-$0.24
52W Low $5.65High $10.45

Volume 0.59M

Average 0.26M

FENC Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Fennec Pharmaceuticals Inc.NASDAQ: FENC

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin widens to -0.8%

Operating margin was -0.8% in Q1 FY2026, up 8.6 pp from a year earlier. On a trailing-twelve-month basis it was -11.0%, up 27.9 pp year over year. Over 3 fiscal years it widened by 1467.1 pp.

Context

  • Operating margin widened in 2 of the last 3 fiscal years.

What to watch

Whether operating margin reaches the consensus estimate from 4 analysts of 19.7% for the fiscal year ending Dec 2026, up from -14.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-0.8%+17.9 pp QoQ
Last fiscal yearDec 2025
-14.2%-19.4 pp YoY
LTMMar 2026
-11.0%+27.9 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+8.6 pp+34.3 pp+25.7 pp
1 year-19.4 pp+33.9 pp+53.4 pp
3 years+1467.1 pp+66.4 pp-1400.7 pp
5 years+68.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-14.2%
Year-over-year change
-19.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How FENC compares with its peers on the latest reported figures

  • FENC's LTM Mar 2026 operating margin of -11.0% is the 2nd highest of the 8 companies compared; the peer median is -503.2%.
  • Its year-over-year change of +27.9 pp is the 5th highest of 7, against a peer median of +272.1 pp.
  • Over three fiscal years its change of +1467.1 pp compares with a peer median of -452.3 pp.
FENC Competitors Peer median
Operating Margin for FENC and competitors
Company Period LTM level YoY 3-year change
BDTXBlack Diamond Therapeutics, Inc.FY202528.4% ——
FENCFennec Pharmaceuticals Inc.LTM Mar 2026-11.0% +27.9 pp+1467.1 pp
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-87.2% +71.2 pp+13.1 pp
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-168.0% +2215.9 pp+769.6 pp
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-503.2% +1496.5 pp—
CRBUCaribou Biosciences, Inc.LTM Mar 2026-1175.7% +473.1 pp-452.3 pp
RNACCartesian Therapeutics, Inc.LTM Mar 2026-5144.5% -4991.1 pp-3113.1 pp
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-134164.4% -122732.2 pp-123394.3 pp
EPRXEupraxia Pharmaceuticals Inc.FY2025— ——
NAUTNautilus Biotechnology, Inc.FY2025— ——
AARDAardvark Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding FENC) -503.2%+272.1 pp-452.3 pp

Competitors are the stored peer set for FENC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.54M21.25M47.54M44.64M
Cost of Revenue086K1.26M3.18M3.76M
Gross Profit01.45M19.99M44.35M40.88M
Gross Margin—94.4%94.1%93.3%91.6%
Research & Development4.98M3.53M56K307K250K
Selling, General & Admin12.24M20.51M32.71M41.48M46.91M
Operating Expenses17.22M24.19M33.05M41.88M47.22M
Depreciation & Amortization16K149K287K800K103K
EBITDA(17.22M)(22.59M)(12.36M)4.8M(7.45M)
EBITDA Margin—-1471.5%-58.2%10.1%-16.7%
Operating Income(17.22M)(22.74M)(13.06M)2.48M(6.35M)
Operating Margin—-1481.3%-61.4%5.2%-14.2%
Interest Income54K195K441K1.59M787K
Interest Expense126K978K3.39M4.07M2.08M
Other Income / Expenses(123K)(976K)(2.99M)(2.55M)(3.29M)
Income Before Tax(17.35M)(23.71M)(16.05M)(71K)(9.64M)
Pre-Tax Margin—-1544.9%-75.5%-0.1%-21.6%
Income Tax Expense000365K106K
Net Income(17.35M)(23.71M)(16.05M)(436K)(9.74M)
Net Margin—-1544.9%-75.5%-0.9%-21.8%
EPS (Basic)(0.67)(0.95)(0.60)(0.02)(0.36)
EPS (Diluted)(0.67)(0.95)(0.60)(0.02)(0.36)
Weighted Avg Shares26.01M26.28M26.57M27.29M28.58M
Weighted Avg Shares (Diluted)26.01M26.28M26.57M27.29M28.58M

Fennec Pharmaceuticals Inc.

NASDAQ:FENC

Intrinsic Alpha fair value

Locked

Current Price

$13.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.